These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18018484)

  • 41. Parkinson's disease: genetic versus toxin-induced rodent models.
    Terzioglu M; Galter D
    FEBS J; 2008 Apr; 275(7):1384-1391. PubMed ID: 18279376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuropathology of Parkinson disease.
    Dickson DW
    Parkinsonism Relat Disord; 2018 Jan; 46 Suppl 1(Suppl 1):S30-S33. PubMed ID: 28780180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical implications of Parkinson's disease genetics.
    Lorincz MT
    Semin Neurol; 2006 Nov; 26(5):492-8. PubMed ID: 17048150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
    Schober A
    Cell Tissue Res; 2004 Oct; 318(1):215-24. PubMed ID: 15503155
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pesticides and Parkinson's disease.
    Sherer TB; Betarbet R; Greenamyre JT
    ScientificWorldJournal; 2001 May; 1():207-8. PubMed ID: 12805673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism.
    Fleming SM; Chesselet MF
    Behav Pharmacol; 2006 Sep; 17(5-6):383-91. PubMed ID: 16940759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GABA: Inhibition brings new excitement in Parkinson's disease.
    Castela I
    Mov Disord; 2016 Mar; 31(3):297. PubMed ID: 26861776
    [No Abstract]   [Full Text] [Related]  

  • 48. Genetic mouse models of parkinsonism: strengths and limitations.
    Fleming SM; Fernagut PO; Chesselet MF
    NeuroRx; 2005 Jul; 2(3):495-503. PubMed ID: 16389313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients.
    Daniel SE; Lees AJ
    J Neurol Neurosurg Psychiatry; 1991 Nov; 54(11):972-5. PubMed ID: 1800669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parkinson's disease: from causes to mechanisms.
    Corti O; Hampe C; Darios F; Ibanez P; Ruberg M; Brice A
    C R Biol; 2005 Feb; 328(2):131-42. PubMed ID: 15770999
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
    Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
    Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
    Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
    Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neurochemical and neurogenetic correlates of Parkinson's disease.
    Mizuno Y; Hattori N; Matsumine H
    J Neurochem; 1998 Sep; 71(3):893-902. PubMed ID: 9721714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primate models of Parkinson's disease.
    Collier TJ; Steece-Collier K; Kordower JH
    Exp Neurol; 2003 Oct; 183(2):258-62. PubMed ID: 14552866
    [No Abstract]   [Full Text] [Related]  

  • 56. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinico-pathological study of a case of familial parkinsonism with striatal degeneration.
    Sakai M; Konagaya M; Kuru S; Kato T; Matsuoka Y; Hashizume Y
    Acta Neuropathol; 2003 Jan; 105(1):76-80. PubMed ID: 12471465
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lewy body-free nigral degeneration--a case report.
    Ishihara K; Nonaka A; Fukui T; Kawamura M; Shiota J; Nakano I
    J Neurol Sci; 2002 Jun; 198(1-2):97-100. PubMed ID: 12039670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday.
    Lees AJ
    Mov Disord; 2007 Sep; 22 Suppl 17():S327-34. PubMed ID: 18175393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson's disease.
    Takahashi-Niki K; Inafune A; Michitani N; Hatakeyama Y; Suzuki K; Sasaki M; Kitamura Y; Niki T; Iguchi-Ariga SM; Ariga H
    J Pharmacol Sci; 2015 Mar; 127(3):305-10. PubMed ID: 25837927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.